Suggest a Correction
Visit CDPH News Releases for daily COVID-19 updates.
En Español: Para obtener información en español, visite nuestra página del Coronavirus 2019 (COVID-19).
As of May 10, 2020, there are a total of 67,939 positive cases and 2,770 deaths in
For county level data, access the COVID-19 Public Dashboard.
For skilled nursing facility data, visit Skilled Nursing Facilites: COVID-19.
The California Department of Public Health is committed to health equity
and collecting more detailed racial and ethnic data that will provide
additional understanding for determining future action. Health outcomes are
affected by forces including structural racism, poverty and the
disproportionate prevalence of underlying conditions such as asthma and heart
disease among Latinos and African American Californians. Only by looking at the
full picture can we understand how to ensure the best outcomes for all
The differences in health outcomes related to COVID-19 are most stark in
COVID-19 deaths. We have nearly complete data on race and ethnicity for
COVID-19 deaths, and we are seeing the following trends. Overall, for adults 18
and older, Latinos, African Americans and Native Hawaiians and Pacific
Islanders are dying at disproportionately higher levels. The proportion of
COVID-19 deaths in African Americans is about double their population
representation across all adult age categories. For Native Hawaiians and
Pacific Islanders, overall numbers are low, but there is a four-fold difference
between the proportion of COVID-19 deaths and their population representation.
More men are dying from COVID-19 than females, in line with national trends.
For the additional information, visit COVID-19 Race and Ethnicity Data.
Testing in California
Twenty-five public health labs in California are testing samples for COVID-19. These labs include the California Department of Public Health’s Laboratory in Richmond, Alameda, Butte, Contra Costa, Fresno, Humboldt, Imperial, Long Beach, Los Angeles, Monterey, Napa-Solano-Yolo-Marin (located in Solano), Orange, Riverside, Sacramento, San Bernardino, San Diego, San Francisco, San Joaquin, San Luis Obispo, San Mateo, Santa Clara, Shasta, Sonoma, Tulare and Ventura County public health laboratories. The Richmond Laboratory will provide diagnostic testing within a 48-hour turnaround time. This means California public health officials will get test results sooner, so that patients will get the best care.
There is currently no vaccine to prevent COVID-19. The best way to prevent illness is to avoid being exposed to this virus. The virus spreads mainly from person-to-person between people who are in close contact with one another (within about 6 feet). This occurs by respiratory droplets produced when an infected person coughs or sneezes. These droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs. Surfaces can also get infected. Older adults and people who have severe underlying medical conditions like hypertension, obesity, heart or lung disease , diabetes
Tuesday, May 5, 2020 9:30 AM
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Today, FitnessAI, the app that uses AI to generate personalized workout plans, has officially rolled out several new features to meet the swelling market demand for at-home fitness applications and equipment during the COVID-19 quarantine.
“FitnessAI is traditionally a strength training app meant for the gym,” details FitnessAI Founder, Jake Mor. “Since gyms are closed, we decided to shift our attention to home workout plans that require absolutely no equipment. Specifically, we’re focusing on two cardio offerings: Home Workouts and The Daily Class.”
FitnessAI is known for its emphasis on strength training, which tailors workouts for users based on their goals. Mor’s algorithm optimizes sets, weights, and reps for optimal muscle growth based on a dataset of more than 6 million workouts from his previous app, Lift Log. FitnessAI has been downloaded over 400K times since the beginning of the year and has gone through the renowned Y Combinator accelerator.
Now, with COVID-19 shuttering businesses and gyms around the country, FitnessAI is catering to the strength training audience that doesn’t want to lose the progress they’ve made while stay home.
“We launched Home Workouts for COVID-19 in Beta at the beginning of the month” says Mor.
“We also hired a trainer to record a 10-minute workout video every single day. Both Home Workouts and The Daily Class are available for free inside the FitnessAI App. The response has been so overwhelmingly positive that we are keeping both features around long term, and forever free.”
The FitnessAI team has also been toiling away at a redesign of the app, which will enable users to customize the app based on the equipment they have at home. “We plan on revamping the weight lifting section of FitnessAI to allow for users to enter exactly what equipment they have, so we can build a strength training routine that uses AI to get them stronger, faster.” says Mor.
People are stocking up on home workout equipment, often paying premiums for basic weights right now. They’re looking for apps like FitnessAI to complement their new circumstances with the same personalization and training regimen as having a professional trainer. FitnessAI, which has already captured a sizable market of people intent on rigorous strength training, is well positioned to onboard more users as workout preferences shift under the sway of quarantine, and personalized exercise enters the home.
“While many apps focus on health and fitness, almost all of them aim to help the casual exerciser, mainly serving as reference manuals for good cardio and conditioning exercises,” says Mor. “FitnessAI takes it a step further by using data to literally hack your body into gaining strength faster. We do this by optimizing an age-old weight lifting process known as progressive overload, which is the act of making your exercises harder every time you workout”.
FitnessAI is an app that generates personalized workout plans for people
Dr. Tom Yadegar, a specialist in critical care medicine who has been treating some of the most extreme cases of the coronavirus, joined Glenn Beck on the radio program Tuesday to share some important information with the public and doctors around the world about treating COVID-19.
As the intensive care unit director at Providence Cedars-Sinai Tarzana Medical Center in California, Yadegar and has been treating patients with COVID-19 for about seven weeks and has not lost a single patient. He was recently asked to command four more regional hospitals because he and his team are performing well above other hospitals in the Los Angeles area.
Yadegar created a protocol to determine which patients with COVID-19 also have what’s called “cytokine storm syndrome” — a process by which the body’s immune system rapidly releases too many cytokines into the blood.
“The immune system kind of goes awry. It doesn’t act normally. The immune system gets super ramped up, and instead of attacking the virus, it attacks the patient’s own vital organs,” Yadegar explained. “It’s actually [the patient’s] own immune system that’s causing the problem, not necessarily the virus.
“Don’t get me wrong. This is a deadly virus. Just like the influenza virus, it can definitely cause pneumonia. It can definitely cause respiratory failure. If the patient has emphysema or heart failure, it can definitely exacerbate those,” he added. “But this [coronavirus] was doing something unique. This was doing something that I really hadn’t seen much in my 20 years, where it was activating the immune system. And then the immune system was causing all the destruction in the lungs.”
Yadegar noted that, while a virus triggering an autoimmune disease is not necessarily an “unknown thing,” the COVID-19 virus “does it at an extraordinary pace” and to a significant number of patients. He stressed the importance of recognizing that not every patient with COVID-19 will develop an autoimmune disease and that every case must be treated individually.
“One thing that I can’t stress any harder to you and your listeners. There isn’t necessarily one test, and there isn’t one particular treatment plan. Every patient has their own kind of individual disease,” he said. “You can’t treat everyone with the same treatments. There isn’t a one-size-fits-all for this disease. You have to do your due diligence. You have to look at the patient in front of you and then, you know, come up with a treatment for the disease that that patient is manifesting. You can’t just go through the ICU, and start handing out these medicines. If you give this medicine to someone who doesn’t need it, you will surely kill them.”
Watch the video below for more details:
In response to the COVID-19 crisis, BlazeTV is offering our BIGGEST discount ever! Get $30 off your subscription when you use promo code GLENN. Claim your special offer at https://get.blazetv.com/glenn/.
Want more from Glenn Beck?
To enjoy more of Glenn’s masterful storytelling, thought-provoking analysis and uncanny ability to make sense of the chaos,
CHICAGO — Oral health can be a concern for people who are sheltering at home.
Dentistry is defined by close contact with patients, and distancing in the era of COVID-19 poses new challenges.
From the air down to the water, a local doctor is bringing high tech infection control to his neighborhood office.
When news of the virus shutting down China made its way to the U.S, Dr. Michael Czarkowski sunk his teeth deep into research.
“We’ve got to come up with a plan and I’m a pro-active person so I tried to figure out what do I have to do in my practice to protect my patients, my team and my family,” he said.
The dentist who typically sees 80 to 100 patients a week now sees about five for emergency procedures only.
And with worries about COVID-19, the phone isn’t exactly ringing off the hook.
“I can just tell some people are nervous,” he said. “But once they see what we’ve done, I can see their anxiety level diminish.”
Air filtration system bathed in UV light cleans particles from the air. The office has its own heating and cooling system.
“We can control the air coming in so we have kind of a positive pressure system you’d see in a hospital operating room,” Czarkowski said.
In the dental chair, droplets are an occupational hazard.
“We have to deal with patients as far as aerosols,” he said. “When we prepare teeth we drill, we create an aerosol. How are we going to control that? What’s the best thing we can do?”
Czarkowski said they use a unit that “takes the aerosol we create when we prepare a tooth for a filling, a crown or a bridge, and sucks it through the machine and runs it through a series of filters.”
Any aerosolized droplets are filtered through a medical grade system that eliminates virus bacteria and mold particles and vented out of the building.
“These units we can rotate the air and clean the air 16 times per hour,” Czarkowski said.
With all the new tools in place, Czarkowski hopes the high tech will ease some of the pain when it comes to a visit to the dentist.
“They know me. They trust me. They expect me to provide and take care of them,” he said. “I take that responsibility seriously.”
All the new technology and the necessary PPE adds up. Czarkowski said he will have to consider an infection control fee to cover the added costs.
“Notable increases” in deaths were seen in March and early April, the team led by the Yale School of Public Health found. This was especially true in New York and New Jersey, states hard-hit by the pandemic.
The study was first reported by the Washington Post.
Using data from the Centers for Disease Control and Prevention, the team found about 15,000 excess deaths from March 1 to April 4. During the same time, states reported 8,000 deaths from Covid-19. “That is close to double,” Dan Weinberger, who studies the epidemiology of infectious diseases at Yale, told CNN.
The team could not show whether the increased deaths were due to coronavirus, Weinberger said. But there are strong indications that they were. For instance, the team also looked at data on doctor visits.
“What we see is that in many states, you see an increase in influenza-like illnesses, and then a week or two later, you see an increase in deaths due to pneumonia and influenza,” Weinberger said. “It provides some confirmation that what we are seeing is related to coronavirus.”
Plus, in especially hard-hit states such as New York and New Jersey, where coronavirus is known to have spread widely and infected many people, overall deaths were far in excess in what would normally have been expected in March.
“In New York City, this discrepancy was even more stark, with three to four times as many excess all-cause deaths as pneumonia and influenza deaths,” the team wrote.
Some states, such as New York, seemed to keep up with the Covid-19 deaths. The state reporting of deaths in the pandemic closely tracked what the Yale team found. But others did not.
The new coronavirus causes respiratory disease, and deaths would presumably be listed among the regular reports of deaths and illness from pneumonia and influenza. But doctors are increasingly reporting other, sometimes fatal, symptoms from Covid-19, including strokes, kidney failure and heart damage.
Patients already weakened by pre-existing conditions such as diabetes, cancer and heart disease may have had a death listed as being due to one of those causes, rather than coronavirus.
Plus, it’s possible that coronavirus lockdowns would have led to a lower-than-average death rate. For instance, if fewer people were driving, traffic deaths could be expected to fall, Weinberger said.
So Weinberger’s team looked at both deaths from pneumonia and influenza, and deaths from all causes.
“We decided to look at all deaths from pneumonia, or all deaths overall, and see how those numbers were changing,” Weinberger said.
The CDC tracks deaths from pneumonia and influenza by the week, and compares them to a baseline of deaths to keep tabs on the annual epidemic of seasonal flu. Separately, the National Center for Health Statistics, part of the CDC, keeps data on all reported deaths.
The Yale-led team subtracted the
SARS-CoV-2, the causative agent of COVID-19, spreads efficiently, with a basic reproductive number of 2.2 to 2.5 determined in Wuhan1,2. The effectiveness of control measures depends on several key epidemiological parameters (Fig. 1a), including the serial interval (duration between symptom onsets of successive cases in a transmission chain) and the incubation period (time between infection and onset of symptoms). Variation between individuals and transmission chains is summarized by the incubation period distribution and the serial interval distribution, respectively. If the observed mean serial interval is shorter than the observed mean incubation period, this indicates that a significant portion of transmission may have occurred before infected persons have developed symptoms. Significant presymptomatic transmission would probably reduce the effectiveness of control measures that are initiated by symptom onset, such as isolation, contact tracing and enhanced hygiene or use of face masks for symptomatic persons.
SARS (severe acute respiratory syndrome) was notable, because infectiousness increased around 7–10 days after symptom onset3,4. Onward transmission can be substantially reduced by containment measures such as isolation and quarantine (Fig. 1a)5. In contrast, influenza is characterized by increased infectiousness shortly around or even before symptom onset6.
In this study, we compared clinical data on virus shedding with separate epidemiologic data on incubation periods and serial intervals between cases in transmission chains, to draw inferences on infectiousness profiles.
Among 94 patients with laboratory-confirmed COVID-19 admitted to Guangzhou Eighth People’s Hospital, 47/94 (50%) were male, the median age was 47 years and 61/93 (66%) were moderately ill (with fever and/or respiratory symptoms and radiographic evidence of pneumonia), but none were classified as ‘severe’ or ‘critical’ on hospital admission (Supplementary Table 1).
A total of 414 throat swabs were collected from these 94 patients, from symptom onset up to 32 days after onset. We detected high viral loads soon after symptom onset, which then gradually decreased towards the detection limit at about day 21. There was no obvious difference in viral loads across sex, age groups and disease severity (Fig. 2).
San Antonio – A Northwest Side dentist said he welcomed Monday’s news from Gov. Greg Abbott about allowing dentists and doctors to reopen, but he admits it’s going to be a little bit of a process to open back up.
Dr. Willie Cantu, who owns Smile Solutions in the 13100 block of Northwest Military Drive, said he will probably will start seeing patients Monday.
Cantu said he and his staff will review their supply of personal protection equipment to make sure they have everything they need.
Texas Gov. Greg Abbott has released his plans to reopen Texas. Here’s what we know
He also said they will probably use their parking lot as a virtual waiting room to make sure social distancing is practiced.
“Today was welcome news, but we’ll have to certainly take baby steps to kind of get back started again because it’s been a bit,” Cantu said. “And, we got to get a lot of folks in, and hopefully everybody remains patient and understanding that we’re trying to work through, you know, some real difficult times with keeping everybody safe while still trying to treat patients.”
Cantu said he understands there will be some patients and staff members who may not be comfortable coming back but he said he’s ready to go back to work and his office will be operating in a way to keep his patients and staff safe.
COVID-19, the respiratory disease caused by the new virus, stands for coronavirus disease 2019. The disease first appeared in late December 2019 in Wuhan, China, but spread around the world in early 2020, causing the World Health Organization to declare a pandemic in March. The first case confirmed in the U.S. was in mid-January and the first case confirmed in San Antonio was in mid-February.
MORE CORONAVIRUS COVERAGE FROM KSAT:
Copyright 2020 by KSAT – All rights reserved.
WASHINGTON, April 14, 2020 /PRNewswire/ — The Emergency Medicine Foundation, a 501(c)(3) nonprofit organization founded by the American College of Emergency Physicians (ACEP) to advance research and education in emergency medicine, has recently announced that it will award up to $100,000 in new research grants to further the medical community’s understanding of and response to the novel coronavirus, COVID-19.
“Emergency Medicine Foundation sponsored research has been defining and refining the practice of emergency medicine for almost 50 years, and it is imperative that we act immediately as new threats, like COVID-19, arise,” said David Wilcox, MD, FACEP, Chair of the EMF Board of Trustees.
Through these funds, the Emergency Medicine Foundation and ACEP seek to effect quick and meaningful change by advancing emergency patient care, improving how our health care system responds and ensuring that our health care workers are protected during this and future pandemics.
Proposals are due June 5, 2020 and eligible applicants must be a United States-based emergency physician as principal or co-principal investigator with a project active and in place by July 1, 2020. Proposal topics may include, but are not limited to, the following:
Click here to read the request for proposals.
The American College of Emergency Physicians (ACEP) is the national medical society representing emergency medicine. Through continuing education, research, public education and advocacy, ACEP advances emergency care on behalf of its 39,000 emergency physician members, and the more than 150 million Americans they treat on an annual basis. For more information, visit www.acep.org and www.emergencyphysicians.org.
The Emergency Medicine Foundation (EMF) is a 501(c)(3) nonprofit organization founded in 1972 by visionary leaders of the American College of Emergency Physicians (ACEP). EMF supports scientifically rigorous research and education that improves the care of the acutely ill and injured. To date, EMF has awarded more than $17 million in research grants to advance emergency medicine science and health policy. For more information visit www.emfoundation.org. Companies or individuals interested in contributing to support emergency medicine research can contact Peggy Brock, EMF Executive Director, at [email protected].
SOURCE Emergency Medicine Foundation
Dr. Denis Vincent was in the business of smiles.
His patients say he was a talented dentist, but remember him most vividly for his gift of making others feel good.
“You knew he had competency, but he was also a people person. He made you feel at ease,” said longtime patient Anne Bethune. “You know when people have that extra gift with their chosen profession? I didn’t spend a lot of time in his chair, but in that time, he nailed personal connection.”
Bethune, whose three sons also saw Vincent, first learned of his death when a friend she had referred to his Vancouver, British Columbia, practice texted that he was believed to be the province’s first COVID-19-related death. He was 62 and had no known pre-existing conditions.
A father of two sons, Vincent was also an avid skier and sailor.
“He gave me hope. This is a tragic loss for our community.”
— Linda Galasso, one of Vincent’s patients
Bethune occasionally spoke with him in the chairlift line at Whistler Blackcomb, a mountain resort about two hours north of Vancouver.
“He had a gifted memory. He genuinely took an interest asking about my boys,” Bethune said.
Linda Galasso, another of Vincent’s patients, says she was as charmed by him as she was pleased by his talent as a dental surgeon.
Also see: Testing for COVID-19 antibodies could be a ‘game-changer’ for the economy but it’s still too early to tell
“He was the most caring doctor I’ve ever had,” Galasso said. “He became a facilitator of my health. He said: ‘I know I can help you get better.’ And he did. He gave me hope. This is a tragic loss for our community.”
Galasso, who saw Vincent about three times a year, was surprised to discover during one visit that her patient file contained a detailed and beautiful hand drawing of her bite.
“The care he put into his work was amazing,” she said.
In conversation with office staff, Galasso learned that Vincent drew the bite of each patient and that his approach had inspired many others in his profession.
Vincent also seemed to have an innate sense of what makes any office a great place to work, Bethune said.
“It was him. The staff was lovely and loyal to him. He chose well, they were each personable, positive, upbeat personalities. They were happy to be there and made going to the dentist a reasonable experience.”
Vincent, who died at home on March 22, was among about 15,000 dentists who had recently attended the Pacific Dental Conference.
Read more stories of the lives lost to COVID-19
After his death, friends observed to the media that he was self-isolating, as directed, and that he had avoided going to a hospital for fear of burdening the health care system as a pandemic was unfolding.
Family lawyer, Bettyann Brownlee, reflected on her longtime client’s legacy: “[he will] be greatly missed. In addition to being a gifted dentist, he had a
Reviewed by Emily Henderson, B.Sc.Apr 8 2020
Philadelphia Eagles owner Jeffrey Lurie today announced a $1 million contribution to Penn Medicine to establish the COVID-19 Immunology Defense Fund, laying the foundation for the world’s foremost experts to fight the novel coronavirus pandemic.
The funds will support both an emerging research program to test front-line health care workers for potential immunity to COVID-19, as well as provide flexibility for Penn Medicine’s researchers–who have overseen the world’s most seminal advances harnessing the power of the immune system to fight disease–to develop real-time research protocols to battle the disease.
The contribution provided by Lurie offers the opportunity for Penn’s leaders to address critically emerging needs as the pandemic evolves. Top priorities range from developing rapid diagnostic testing, to finding drugs that work against the virus, to developing potential vaccines. In the coming days, serology tests will be deployed across multiple research studies, including for health care workers and recovered COVID-19 patients, helping scientists to determine if a person has antibodies against the virus, which could help to enhance hospitals’ knowledge about which staff may be immune to the disease. These critical projects will enhance understanding of how to protect frontline health care workers, and drive knowledge to advance options for treatments and vaccines in the crucial months ahead.
We are in the midst of a humanitarian crisis that is affecting all of us in so many ways. Every passing day brings new stories of heartbreaking tragedy, inspirational courage, and hopeful innovation. We can and will get through this, but only if we work together, care for each other, and focus our attention and resources towards sustainable strategies. There are so many individuals and organizations who are making daily sacrifices, and we are incredibly thankful for their dedication and bravery. We must continue to support these efforts in every way that we can, while also seeking a solution that will help us move forward.
We have reached a critical point in our fight against COVID-19 in which testing for antibodies is absolutely essential both to protect our front-line workers in the short term and to develop treatments and vaccines that will save lives and help defeat the virus. With that in mind, I am proud to offer my support to Penn Medicine’s research efforts by establishing the COVID-19 Immunology Defense Fund. This fund will aid Penn’s multi-disciplinary approach in immunology, merging research in diagnostics, therapeutics and vaccine development. Researchers from those three areas will work hand- in- hand and rely upon one another to create an immediate and lasting impact both locally and worldwide.”
Jeffrey Lurie, Philadelphia Eagles owner
Armed with the largest single-institution immunology community in the country, Penn has notched a string of U.S. Food and Drug Administration approvals for immune-based therapies in the past three years. Penn’s best-in-class infrastructure — from well-established bench-to-bedside pipelines, to high-level biosafety facilities to test treatments with live virus– has led its immunologists to international renown for the discovery,